migraine | pharmaphorum

Skip to main content

Friday 10 April 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

migraine

News

Aimovig

Novartis/Amgen's migraine drug hits market at lower than exp...

The FDA has approved the first in a new class of migraine drugs, Novartis and Amgen’s Aimovig, and at a lower than expected list price of $6,900.

News

A sad young woman is sitting in her kitchen with a headache

Lilly drug scrapes through cluster headache trial

FDA to make decision on Amgen drug tomorrow

News

A sad young woman is sitting in her kitchen with a headache

Lilly and Alder showcase latest migraine drug data

Lilly and Alder take on the might of Novartis and Amgen

News

Novartis HQ

Novartis/Amgen migraine jab works in tough-to-treat patients

Novartis continues to build the case for its Aimovig migraine injection,with data showing it works in a tough-to-treat patient group.

News

Sosei

Sosei see Teva pipeline cull as an opportunity

Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.

News

Neuron_in_tissue_culture

Novartis/Amgen migraine drug reduces attacks after others fa...

Aimovig notches up another late-stage trial success

Load more results

Editor's Picks

Gilead strikes again, penning $5bn deal to buy Tubulis

US judge blocks bid to curb abortion pill access

Kennedy changes vaccine panel charter after legal setback

Jeito closes 'record' $1.2bn Europe-focused biopharma fund

Boehringer transfers schizophrenia DTx selling rights to Click

News

Two boxes and doses of Senju

Senju launches first-in-class dry eye disease drug in Japan

Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights further

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company